Headlines about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.2953689022409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several research firms have issued reports on VRNA. Stifel Nicolaus set a $25.00 target price on Verona Pharma plc – American Depositary Share and gave the stock a “buy” rating in a research report on Friday, March 2nd. Berenberg Bank began coverage on Verona Pharma plc – American Depositary Share in a research report on Tuesday, February 20th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Verona Pharma plc – American Depositary Share in a research report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Verona Pharma plc – American Depositary Share has an average rating of “Buy” and a consensus price target of $25.67.
Shares of Verona Pharma plc – American Depositary Share (NASDAQ VRNA) traded down $0.04 during mid-day trading on Wednesday, hitting $15.76. The company had a trading volume of 26,276 shares, compared to its average volume of 6,345. Verona Pharma plc – American Depositary Share has a one year low of $10.44 and a one year high of $17.50.
Verona Pharma plc – American Depositary Share Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.